4Lamba JK, Lin YS, Thummel K, et al. Common allelic variants ofcytochrome P4503A4 and their prevalence in different populations [J]. Pharmacogenetics, 2002,12(2) , 121-132.
5Bakken GV, Molden E, Knutsen K, et al. Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro [J]. Drug Metab Dispos,2012, 40(9) : 1778-1784.
6Wang D, Guo Y, Wrighton SA, et al. Intronic polymorphism in CYP3A4affects hepatic expression and response to statin drugs [ J ]. Pharmacogenomics, 2011,11 ( 4 ) : 274-286.
7van der Weide K, van der Weide J. The influence of the CYP3A4- 22 polymorphism on serum concentration of quetiapine in psychiatric patients [ J]. J Chin Psychopharmacol, 2014,34(2) : 256-260.
9Langaee TY, Gong Y, Yarandi HN, et al. Association of CYP3A5 polymorphisms with hypertension and antihypertensive response to verapamil [ J ]. Clin Pharmacol Ther, 2007, 81 (3) : 386-391.
10Liu L, Yang L, Zhang YC, et al. Polymorphisms of drug- metabolizing enzymes genes in a Han Chinese population [ J ]. Zhonghua Yi Xue Za Zhi,2009, 89 (38) : 2675-2681.
10RUF HH, WENDE P, ULLRICH V. Models for ferric cyto- chrome P550. Characterization of hemin mercaptide complexes by electronlc and E SR spectral [J]. J lnorg Biochem, 1979,11 (3) : 189 -204.
